Država: Izrael
Jezik: angleščina
Source: Ministry of Health
LINEZOLID
PFIZER PFE PHARMACEUTICALS ISRAEL LTD
J01XX08
TABLETS
LINEZOLID 600 MG
PER OS
Required
PFIZER INC, USA
LINEZOLID
Therapy is indicated only when an organism resistant to all other antibiotics is suspected. Zyvoxid is indicated in adult and pediatric patients for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: 1) Pneumonia - community acquired and nosocomial pneumonia including multi drug resistant streptococcus pneumonia (MDRSP). 2) Skin and soft tissue infections including diabetic foot infections. 3) Enterococcal infections. Combination therapy may be indicated if a concomitant Gram negative pathogen is documented or suspected.
2021-06-30
.بيبطلا ىلإ ً اروف هجوت - ةيلصلأا ضارعلأا تداعو ءاودلا لوانت نع تفقوت اذإ .هب ىصوملا يئاودلا رادقملا زواجت زوجي لا .يلطم هنلأ صرقلا غضم/رطش/قحس عنم ُ ي ً اروف هجوت ،ءاودلا نم أطخلاب لفط علب اذإ وأ ً اطرفم ً ايئاود ً ارادقم تلوانت اذإ .ءاودلا ةبلع كعم رضحأو ىفشتسملا يف ئراوطلا ةفرغ ىلإ وأ بيبطلا ىلإ لاح يئاود رادقم لوانت بجيف ،ددحملا تقولا يف ءاودلا اذه لوانت تيسن اذإ ،اذه يئاودلا رادقملا نم ً اءدب يلاتلا يئاودلا رادقملا دعوم باسح بجي .كلذب كركذت !فعاضم يئاود رادقم لوانت لاوحلأا نم لاح يأب زوجي لا نكلو ءاودلاب جلاعلا نع فقوتلا زوجي لا .بيبطلا ةيصوت بسح جلاعلا ىلع ةبظاوملا بجي .ةيحصلا كتلاح ىلع نسحت أرط ولو ىتح ،بيبطلا ةراشتسإ نودب رادقملا نم دكأتلاو ءاودلا عباط صيخشت بجي !ةمتعلا يف ةيودأ لوانت زوجي لا .كلذ رملأا مزل اذإ ةيبطلا تاراظنلا عض .ءاود اهيف لوانتت ةرم لك يف يئاودلا .يلديصلا وأ بيبطلا رشتسإ ،ءاودلا لامعتسإ لوح ةيفاضإ ةلئسأ كيدل ترفوت اذإ ةيبناجلا ضارعلأا .4 .نيلمعتسملا ضعب ىدل ةيبناج ً اضارعأ ببسي دق ديسكوڨيز لامعتسإ نإ ،ءاود لكب امك .اهنم ً ايأ يناعت لاأ زئاجلا نم .ةيبناجلا ضارعلأا ةمئاق نم شهدنت لا :)اهعويشو( ديسكوڨيز ـل ةريطخلا ةيبناجلا ضارعلأا :لاح يف بيبطلا ىلإ ً اروف هجوتلاو لامعتسلإا نع فقوتلا بجي ةقطنم يف ة Preberite celoten dokument
Zyvoxid LPD CC 131222 Page 1 of 21 2020-0065057 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Zyvoxid® I.V. 2 mg/ml Solution for Infusion Zyvoxid® 600 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Solution for infusion: 1 ml contains 2 mg linezolid. Excipients with known effect: each 1 ml also contains 45.7 mg glucose and 0.38 mg sodium. 600 mg tablet: Each tablet contains 600 mg linezolid. _ _ For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for infusion: Isotonic, clear, colourless to yellow solution with pH range of 4.4-5.2. 600mg tablet: A white to off-white coated tablet with “ZYV” debossed on one side and “600” debossed on the other. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Therapy is indicated only when an organism resistant to all other antibiotics is suspected. Zyvoxid is indicated in adult and pediatric patients for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: 1) Pneumonia - community acquired and nosocomial pneumonia including multi drug resistant streptococcus pneumonia (MDRSP). 2) Skin and soft tissue infections including diabetic foot infections. 3) Enterococcal infections. Linezolid is active against Gram–positive bacteria only. Linezolid has no clinical activity against Gram–negative pathogens. Specific Gram- negative therapy is required if a concomitant Gram-negative pathogen is documented or suspected (see section 4.4 and 5.1). Linezolid should only be initiated after consultation with a relevant specialist such as a microbiologist or infectious diseases specialist. CONSIDERATION SHOULD BE GIVEN TO OFFICIAL GUIDANCE ON THE APPROPRIATE USE OF ANTIBACTERIAL AGENTS. Zyvoxid LPD CC 131222 Page 2 of 21 2020-0065057 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Zyvoxid ® solution for infusion and tablets may be used as initial therapy. Patients who commence treatment on the parenteral formulation may Preberite celoten dokument